Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
17. Dezember 2024 13:32 ET
|
Tevogen Bio Inc
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
10. Dezember 2024 15:13 ET
|
Tevogen Bio Inc
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
05. November 2024 16:43 ET
|
Tevogen Bio Inc
Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending.Approximately 78% of Tevogen Bio's common stock is held by company...
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
23. Oktober 2024 08:35 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
22. Oktober 2024 14:30 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
21. Oktober 2024 15:58 ET
|
Tevogen Bio Inc
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days
21. Oktober 2024 13:56 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
17. Oktober 2024 09:32 ET
|
Tevogen Bio Inc
Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success...
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion
17. Oktober 2024 07:54 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio (“Tevogen” or “Tevogen Bio...
Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality
16. Oktober 2024 16:30 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...